TRiCares Announces First Topaz Implantation in EU Pivotal Study
24. September 2024 02:00 ET
|
TRiCares SAS
TRiCares Announces First Topaz Implantation in EU Pivotal StudyParis, France and Munich, Germany, September 24, 2024 – TRiCares SAS (“TRiCares”), a company pioneering a minimally-invasive tricuspid...
TRiCares Raises $50m in Series D Financing to Support Upcoming Clinical Milestones
25. Juli 2024 02:00 ET
|
TRiCares SAS
TRiCares Raises $50m in Series D Financing to Support Upcoming Clinical Milestones Paris, France and Munich, Germany, July 25, 2024 – TRiCares SAS (“TRiCares”), a privately held pioneer in the field...
Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer
25. März 2024 02:00 ET
|
TRiCares SAS
PRESS RELEASE Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer Paris, France and Munich, Germany, March 25, 2024 – TRiCares SAS (“TRiCares”) a...
TRiCares Announces Successful Implantation of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System in Patient with a Pacemaker
21. Dezember 2023 02:00 ET
|
TRiCares SAS
TRiCares Announces Successful Implantation of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System in Patient with a Pacemaker Paris, France and Munich, Germany, December 21, 2023 –...
TRiCares Successfully Closes Series C Financing, Raising €51m to Fund Further Development and Clinical Trials of Minimally Invasive Treatment for Tricuspid Regurgitation
06. Dezember 2022 02:00 ET
|
TRiCares SAS
TRiCares Successfully Closes Series C Financing, Raising €51m to Fund Further Development and Clinical Trials of Minimally Invasive Treatment for Tricuspid Regurgitation Paris, France and Munich,...
TRiCares Raises €47m in a First Closing of its Series C Financing to Fund Further Development of Minimally Invasive Treatment for Tricuspid Regurgitation
15. September 2022 07:00 ET
|
TRiCares SAS
TRiCares Raises €47m in a First Closing of its Series C Financing to Fund Further Development of Minimally Invasive Treatment for Tricuspid Regurgitation Paris, France and Munich, Germany, September...
TRiCares réalise une Série B de €22 Millions ($25.4 Millions) pour le développement de son traitement mini-invasif de la régurgitation tricuspide
04. Juni 2018 02:00 ET
|
TRiCares SAS
TRiCares réalise une Série B de €22 Millions ($25.4 Millions) pour le développement de son traitement mini-invasif de la régurgitation tricuspide Paris (France) et Munich (Allemagne), 4 juin 2018 -...
TRiCares schließt eine Finanzierungsrunde der Serie B in Höhe von € 22 Millionen ($ 25,4 Millionen) zur Investition in die Entwicklung einer minimal invasiven Behandlung von Trikuspidal-Insuffizienz
04. Juni 2018 02:00 ET
|
TRiCares SAS
TRiCares schließt eine Finanzierungsrunde der Serie B in Höhe von € 22 Millionen ($ 25,4 Millionen) zur Investition in die Entwicklung einer minimal invasiven Behandlung von Trikuspidal-Insuffizienz ...
TRiCares Closes €22 Million ($25.4 Million) Series B Financing Round to Fund Development of Minimally Invasive Treatment of Tricuspid Regurgitation
04. Juni 2018 02:00 ET
|
TRiCares SAS
TRiCares Closes €22 Million ($25.4 Million) Series B Financing Round to Fund Development of Minimally Invasive Treatment of Tricuspid Regurgitation Paris, France and Munich, Germany, June 4, 2018 -...